107 related articles for article (PubMed ID: 20409618)
1. Inhibitors of the RET tyrosine kinase based on a 2-(alkylsulfanyl)-4-(3-thienyl)nicotinonitrile scaffold.
Brandt W; Mologni L; Preu L; Lemcke T; Gambacorti-Passerini C; Kunick C
Eur J Med Chem; 2010 Jul; 45(7):2919-27. PubMed ID: 20409618
[TBL] [Abstract][Full Text] [Related]
2. The discovery of substituted 4-(3-hydroxyanilino)-quinolines as potent RET kinase inhibitors.
Graham Robinett R; Freemerman AJ; Skinner MA; Shewchuk L; Lackey K
Bioorg Med Chem Lett; 2007 Nov; 17(21):5886-93. PubMed ID: 17884497
[TBL] [Abstract][Full Text] [Related]
3. Synthesis, modeling, and RET protein kinase inhibitory activity of 3- and 4-substituted beta-carbolin-1-ones.
Cincinelli R; Cassinelli G; Dallavalle S; Lanzi C; Merlini L; Botta M; Tuccinardi T; Martinelli A; Penco S; Zunino F
J Med Chem; 2008 Dec; 51(24):7777-87. PubMed ID: 19053769
[TBL] [Abstract][Full Text] [Related]
4. Novel 5,7-disubstituted 6-amino-5H-pyrrolo[3,2-b]pyrazine-2,3-dicarbonitriles, the promising protein kinase inhibitors with antiproliferative activity.
Dubinina GG; Platonov MO; Golovach SM; Borysko PO; Tolmachov AO; Volovenko YM
Eur J Med Chem; 2006 Jun; 41(6):727-37. PubMed ID: 16675067
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of RET tyrosine kinase by SU5416.
Mologni L; Sala E; Cazzaniga S; Rostagno R; Kuoni T; Puttini M; Bain J; Cleris L; Redaelli S; Riva B; Formelli F; Scapozza L; Gambacorti-Passerini C
J Mol Endocrinol; 2006 Oct; 37(2):199-212. PubMed ID: 17032739
[TBL] [Abstract][Full Text] [Related]
6. Design and synthesis of 3-substituted benzamide derivatives as Bcr-Abl kinase inhibitors.
Asaki T; Sugiyama Y; Hamamoto T; Higashioka M; Umehara M; Naito H; Niwa T
Bioorg Med Chem Lett; 2006 Mar; 16(5):1421-5. PubMed ID: 16332440
[TBL] [Abstract][Full Text] [Related]
7. Structural insights into the ATP binding pocket of the anaplastic lymphoma kinase by site-directed mutagenesis, inhibitor binding analysis, and homology modeling.
Gunby RH; Ahmed S; Sottocornola R; Gasser M; Redaelli S; Mologni L; Tartari CJ; Belloni V; Gambacorti-Passerini C; Scapozza L
J Med Chem; 2006 Sep; 49(19):5759-68. PubMed ID: 16970400
[TBL] [Abstract][Full Text] [Related]
8. ATP competitive inhibitors of D-alanine-D-alanine ligase based on protein kinase inhibitor scaffolds.
Triola G; Wetzel S; Ellinger B; Koch MA; Hübel K; Rauh D; Waldmann H
Bioorg Med Chem; 2009 Feb; 17(3):1079-87. PubMed ID: 18321716
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and Src kinase inhibitory activity of 2-phenyl- and 2-thienyl-7-phenylaminothieno[3,2-b]pyridine-6-carbonitriles.
Boschelli DH; Wu B; Barrios Sosa AC; Durutlic H; Chen JJ; Wang Y; Golas JM; Lucas J; Boschelli F
J Med Chem; 2005 Jun; 48(11):3891-902. PubMed ID: 15916442
[TBL] [Abstract][Full Text] [Related]
10. Pharmacophore modeling and virtual screening to identify potential RET kinase inhibitors.
Shih KC; Shiau CW; Chen TS; Ko CH; Lin CL; Lin CY; Hwang CS; Tang CY; Chen WR; Huang JW
Bioorg Med Chem Lett; 2011 Aug; 21(15):4490-7. PubMed ID: 21724393
[TBL] [Abstract][Full Text] [Related]
11. Development of new fluorescent xanthines as kinase inhibitors.
Kim D; Jun H; Lee H; Hong SS; Hong S
Org Lett; 2010 Mar; 12(6):1212-5. PubMed ID: 20184370
[TBL] [Abstract][Full Text] [Related]
12. Structure-based optimization of potent and selective inhibitors of the tyrosine kinase erythropoietin producing human hepatocellular carcinoma receptor B4 (EphB4).
Lafleur K; Huang D; Zhou T; Caflisch A; Nevado C
J Med Chem; 2009 Oct; 52(20):6433-46. PubMed ID: 19788238
[TBL] [Abstract][Full Text] [Related]
13. Systematic Analysis of Tyrosine Kinase Inhibitor Response to RET Gatekeeper Mutations in Thyroid Cancer.
Meng S; Wu H; Wang J; Qiu Q
Mol Inform; 2016 Oct; 35(10):495-505. PubMed ID: 27712045
[TBL] [Abstract][Full Text] [Related]
14. Discovery of a novel protein kinase B inhibitor by structure-based virtual screening.
Medina-Franco JL; Giulianotti MA; Yu Y; Shen L; Yao L; Singh N
Bioorg Med Chem Lett; 2009 Aug; 19(16):4634-8. PubMed ID: 19604696
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and RET protein kinase inhibitory activity of 3-arylureidobenzylidene-indolin-2-ones.
Rizzi E; Cassinelli G; Dallavalle S; Lanzi C; Cincinelli R; Nannei R; Cuccuru G; Zunino F
Bioorg Med Chem Lett; 2007 Jul; 17(14):3962-8. PubMed ID: 17499504
[TBL] [Abstract][Full Text] [Related]
16. Structural modification of an EGFR inhibitor that showed weak off-target activity against RET leading to the discovery of a potent RET inhibitor.
Sun QZ; Xu Y; Liu JJ; Zhang CH; Wang ZR; Zheng RL; Wang WJ; Li LL; Yang SY
Mol Divers; 2014 May; 18(2):403-9. PubMed ID: 24515340
[TBL] [Abstract][Full Text] [Related]
17. An orally available tyrosine kinase ALK and RET dual inhibitor bearing the tetracyclic benzo[b]carbazolone core.
Song Z; Xia Z; Ji Y; Xing L; Gao Y; Ai J; Geng M; Zhang A
Eur J Med Chem; 2016 Aug; 118():244-9. PubMed ID: 27131066
[TBL] [Abstract][Full Text] [Related]
18. In silico profiling and structural insights of missense mutations in RET protein kinase domain by molecular dynamics and docking approach.
George Priya Doss C; Rajith B; Chakraboty C; Balaji V; Magesh R; Gowthami B; Menon S; Swati M; Trivedi M; Paul J; Vasan R; Das M
Mol Biosyst; 2014 Mar; 10(3):421-36. PubMed ID: 24336963
[TBL] [Abstract][Full Text] [Related]
19. In vitro and in vivo evaluation of 6-aminopyrazolyl-pyridine-3-carbonitriles as JAK2 kinase inhibitors.
Wang T; Ioannidis S; Almeida L; Block MH; Davies AM; Lamb ML; Scott DA; Su M; Zhang HJ; Alimzhanov M; Bebernitz G; Bell K; Zinda M
Bioorg Med Chem Lett; 2011 May; 21(10):2958-61. PubMed ID: 21493067
[TBL] [Abstract][Full Text] [Related]
20. Identification of a novel 5-amino-3-(5-cyclopropylisoxazol-3-yl)-1-isopropyl-1H-pyrazole-4-carboxamide as a specific RET kinase inhibitor.
Yoon H; Shin I; Nam Y; Kim ND; Lee KB; Sim T
Eur J Med Chem; 2017 Jan; 125():1145-1155. PubMed ID: 27814560
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
